research use only

Radiprodil (RGH-896) NMDAR antagonist

Name: Radiprodil (RGH-896)
SKU: S6644
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S6644

Radiprodil (RGH-896) is a NR2B-selective NMDA receptor antagonist, initially developed for the treatment of neuropathic pain.

Chemical Structure

Molecular Weight: 397.40

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S664401 DMSO]79 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.7%

99.7

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel GluR MAO Beta Amyloid P2 Receptor Trk receptor Serotonin Transporter Notch Cannabinoid Receptor P-gp CaMK Opioid Receptor BACE Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor BChE Adenosine Deaminase CCK receptor MT Receptor
Related Products	(+)-Dizocilpine (MK 801) Maleate (-)-Dizocilpine (MK 801) Maleate NMDA (N-Methyl-D-aspartic acid) Ifenprodil Tartrate Memantine HCl Spermidine trihydrochloride Kynurenic acid Mephenesin Quinolinic acid NMDAR antagonist 1 D-Aspartic acid D-AP5 Linalool Pulchinenoside A Tiletamine Hydrochloride L-Phenylalanine Ifenprodil Rapastinel (GLYX-13) Deudextromethorphan (AVP-786) (R)-Serine Cycloleucine PEAQX D-Alanine NMDA Receptor 1 (GluN1) Antibody [D10D12] Sarcosine Phospho-NMDAR2B (Ser1303) Antibody [G14F14] TCN 201 Eliprodil (SL-820715) PSD95 Antibody [F17C8] 6-Methoxy-2-naphthoic acid

Chemical Information, Storage & Stability

Molecular Weight	397.40	Formula	C₂₁H₂₀FN₃O₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	496054-87-6	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1CN(CCC1CC2=CC=C(C=C2)F)C(=O)C(=O)NC3=CC4=C(C=C3)NC(=O)O4

Solubility

In vitro
Batch:

DMSO : 79 mg/mL (198.79 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06392009	Recruiting	Tuberous Sclerosis Complex\|Focal Cortical Dysplasia	GRIN Therapeutics Inc.	May 2024	Phase 1\|Phase 2
NCT05818943	Recruiting	GRIN-related Disorders	GRIN Therapeutics Inc.	March 7 2023	Phase 1
NCT02829827	Terminated	Infantile Spasms (IS)	UCB Biopharma S.P.R.L.\|UCB Pharma	December 4 2017	Phase 2
NCT02647697	Completed	Healthy Volunteers	UCB Biopharma S.P.R.L.\|PRA Health Sciences\|UCB Pharma	January 2016	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):